Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium von Khaki, A.R., Wise-Draper, T.M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Painter, C.A., Peters, S., Rini, B.I., Mishra, S., Rivera, D.R., Acoba, J.D., Bashir, B., Bekaii-Saab, T., Berg, S., Bernicker, E.H., Bilen, M.A., Bindal, P., Bishnoi, R., Bouganim, N., Bowles, D.W., Cabal, A., Caimi, P.F., Crowell, J., Desai, A., Dixon, B., Doroshow, D.B., Durbin, E.B., Farmakiotis, D., Fazio, A., Fecher, L.A., Friese, C.R., Fu, J., Gadgeel, S.M., Glover, M.J., Goyal, S., Grover, P., Gulati, S., Gupta, S., Halabi, S., Halfdanarson, T.R., Halmos, B., Hausrath, D.J., Hawley, J.E., Hsu, E., Jani, C., Jayaraj, A., Johnson, D.B., Kasi, A., Khan, H., Kuderer, N.M., Kwon, D.H., Li, A., Loaiza-Bonilla, A., Low, C.A., Lustberg, M.B., Lyman, G.H., McKay, R.R., McNair, C., Menon, H., Mesa, R.A., Mundt, D., Nagaraj, G., Nakasone, E.S., Nizam, A., Nock, N.L., Patel, J.M., Patel, K.G., Peddi, P., Pennell, N.A., Piper-Vallillo, A.J., Puc, M., Reeves, M.E., Reuben, D.Y., Rosovsky, R.P., Salazar, M., Schmidt, A.L., Schwartz, G.K., Shah, M.R., Shah, S.A., Shah, C., Shaya, J.A., Stockerl-Goldstein, K.E., Streckfuss, M., Subbiah, S., Tachiki, L., Thakkar, A., Tucker, M.D., Verma, A.K., Vinh, D.C., Weiss, M., Wu, J.T., Wulff-Burchfield, E., Xie, Z., Yu, P.P., Zhou, A.Y., Zhu, H., Zubiri, L., Warner, J.L., Lopes, GdL

Volltext

373 The oral MEK1/MEK2 inhibitor, GSK1120212, effectively inhibits the MAPK pathway: pharmacokinetic, pharmacodynamic, and clinical response relationship von Gordon, M.S, Infante, J.R, Messersmith, W, Fecher, L.A, Vogelzang, N.J, Cox, D, DeMarini, D.J, Xu, Y, Peddareddigari, V, Falchook, G

Volltext